Posology and usage patterns of Angiox®: Dose(s) and time of bolus and infusion administered
Time frame · from hospital admission until hospital discharge, or 7 days after administration (which ever is earlier).
Utilisation of Angiox® in European Practice
Status
Completed
Phase
Not applicable
Enrollment
2,019
Locations
2
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The objective of this study is to determine utilisation patterns in patients receiving Angiox® in participating European centres. Additionally, through the collection of descriptive safety and outcomes data, this study will contribute to the Risk Management strategy for Europe
Interventions
Treatment arms and agents.
No intervention details reported.
Timeline
From registration to results.
First posted
Nov 11, 2009
Study start
May 2009
Primary completion
Oct 2010
Study completion
Dec 2010
Results posted
Not reported
Registry updated
Jan 19, 2012
Outcomes
What the study measures.
Primary outcomes
Secondary outcomes
Death Myocardial infarction Unplanned revascularisation Stroke Major* and minor bleeding Thrombocytopenia Stent thrombosis Adverse events and serious adverse events
Time frame · measured in-hospital (prior to discharge), and at post-hospital discharge in outpatient as per local practice (30 days)
Eligibility
Who can take part.
- Minimum age
- Not reported
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Eligible for, and receive treatment with Angiox®. * Willing and able to provide written informed consent to the use of their data in accordance with relevant local Data Protection laws, policies and regulations Exclusion Criteria: * Participation in other interventional clinical research studies involving the evaluation of investigational drugs, including Angiox®, or devices at the time of enrolment. * Patients not eligible for treatment for Angiox®.
Study locations
2 registered sites.
France · Germany. Showing up to 24 locations stored in the fast local snapshot.
Centre Hospitalier Universitaire de Caen
Caen, France
Medizinische Klinik I Kardiologie/Pneumologie/Internistische
Rostock, Germany
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Bivalirudin.
NCT IDStudyPhase / statusEnrollmentUpdated
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Duke University · Coronavirus Infection (COVID-19) · Pulmonary Arterial Hypertension
Not applicable
Recruiting
5,000
2026-07
BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation
Sydney Local Health District · Extracorporeal Membrane Oxygenation Complication
Phase 2
Recruiting
80
2026-05
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
Xiaotong Hou · Extracorporeal Membrane Oxygenation Complication
Not applicable
Recruiting
154
2026-04
Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes
Shenyang Northern Hospital · Percutaneous Coronary Intervention · High Bleeding Risk
Phase 4
Not yet recruiting
5,270
2026-02
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
Stanford University · Heart Failure · Cardiogenic Shock
Phase 2
Recruiting
50
2026-01
A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction
NYU Langone Health · Coronary Microvascular Disease · Ischemic Heart Disease
Not applicable
Active, not recruiting
206
2025-11
Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI
Shenyang Northern Hospital · ST Elevation Myocardial Infarction
Not applicable
Completed
6,016
2025-08
A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.
Peking University First Hospital · Coronary Microvascular Dysfunction
Phase 4
Recruiting
70
2025-08
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.